The electronic medicines compendium is where UK medicines information becomes product-specific: it hosts regulated documents for particular medicines, strengths and formulations. This practical guide explains what eMC contains, how to read an SmPC quickly, and why selecting the exact product matters. For the wider source framework, see our eMC and NICE CKS comparison.
What emc contains, and where it comes from
Four document families matter: Summaries of Product Characteristics, the professional-facing authorised text; Patient Information Leaflets, the version dispensed in the box; Risk Minimisation Materials for selected products; and direct healthcare-professional communications and safety updates. Provenance matters for how you read them: the marketing-authorisation holder prepares the documentation, the regulator approves it, and the approved text is what emc publishes. That makes emc authoritative about the product and its licence, and it also means an SmPC is not independent comparative clinical guidance; it is the manufacturer's authorised text, product-specific by design, cautious by regulatory nature, and silent about the neighbouring product's differences. Its strength is exactness, not judgement.
Reading an SmPC in ninety seconds
The section numbering is standardised, so navigation is a learnable reflex. Section 2 gives qualitative and quantitative composition; 4.1 the licensed indications; 4.2 posology and administration method; 4.3 contraindications; 4.4 special warnings and precautions; 4.5 interactions; 4.6 fertility, pregnancy and lactation; 4.8 undesirable effects; 6.1 the full excipient list; 6.3 and 6.4 shelf life and storage, which matter more than people expect for liquids and reconstituted products; and 6.6 handling and disposal. The professional habit: jump to the numbered section your question lives in rather than reading linearly, and cross-check 4.3 and 4.4 whenever 4.2 sent you there.
The most common mistake
Opening the first SmPC the search returns and assuming it speaks for the medicine. It does not; it speaks for one product, and products sharing an active ingredient can differ in licence, population, excipients, device and administration instructions. Always confirm four things before reading: manufacturer, strength, formulation, route. The apixaban suspensions make the point cleanly: two distinct 1 mg/ml oral suspension products hold separate SmPCs, and details such as excipients and supplied devices are product-level facts, which is why the iatroX apixaban page links each preparation to its own current selected SmPC rather than to a generic one. The same logic runs through amoxicillin, where capsules, multiple liquids and sodium-containing injectables each carry their own storage, reconstitution and compatibility wording, and through ibuprofen, where one ingredient spans ordinary tablets, children's liquids, topical gels, adult intravenous products and the specialist neonatal preparation, same molecule, materially different documents.
How iatroX shortens the journey
The workflow that makes emc fast: start at the medicine-level page on iatroX Medicines, identify which formulations and routes exist and which distinctions are clinically live, then follow the selected SmPC link for the precise product in hand. The medicine page does the orientation, what exists, what differs, what to watch, and emc does what only emc can, the authorised exact text; the review date and source list on each iatroX page keep the chain inspectable. When the product in front of you is not the one linked, emc's own search finishes the job, with the four-point check above applied.
Frequently asked questions
Should patients read SmPCs?
The PIL is the patient-facing document and travels in the box; the SmPC is written for professionals, and sending a worried patient into section 4.8 unbriefed is rarely a kindness. Patient conversations go better through the PIL or a patient-facing source, with the SmPC behind you.
Why does SmPC wording sometimes feel more cautious than practice?
Because it is a regulatory text bound to the evidence submitted for that product's licence, which can lag or sit narrower than clinical consensus; that is precisely when specialist sources and local guidance earn their place in the stack: /blog?q=prescribing.
Are all UK products on emc?
Most, not all; where a product is absent, the MHRA's product-information routes and the manufacturer's medical-information line fill the gap. Absence from emc is a prompt to check harder, not evidence of a problem.
What are Risk Minimisation Materials, practically?
Additional regulator-required materials for selected higher-risk products, prescriber checklists, patient alert cards, dosing guides, published on emc alongside the SmPC. Where they exist for a medicine you prescribe, they are part of the job, not optional reading, and the anticoagulant alert card is the everyday example most clinicians already know.
Does emc cover Northern Ireland differences?
Product information reflects the applicable licensing arrangements, which have diverged in places; where a product's position differs across the UK, the authorised documents and MHRA guidance carry it. When in doubt for an NI patient, check the specific product entry rather than assuming GB equivalence.